Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential

Experimental Hematology & Oncology

卷:11

Review

Wenbo Wang¹  Xiang Yuan²  Xuejiao Yang³  Xiao Wang³  Yueying Wang³ 

[1] Department of Oncology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, 200072, Shanghai, China;

[2] Department of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, 610041, Chengdu, China;

[3] Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 200025, Shanghai, China;

关键词: T cells;    Natural killer cells;    Chimeric antigen receptor;    Cancer;    Cellular immunotherapy;   

DOI  :  10.1186/s40164-022-00341-7

 received in 2022-08-22, accepted in 2022-09-29,  发布年份 2022

来源: Springer

【 摘 要 】

Chimeric antigen receptor (CAR)-engineered T (CAR-T) cells have obtained prominent achievement in the clinical immunotherapy of hematological malignant tumors, leading to a rapid development of cellular immunotherapy in cancer treatment. Scientists are also aware of the prospective advantages of CAR engineering in cellular immunotherapy. Due to various limitations such as the serious side effects of CAR-T therapy, researchers began to investigate other immune cells for CAR modification. Natural killer (NK) cells are critical innate immune cells with the characteristic of non-specifically recognizing target cells and with the potential to become “off-the-shelf” products. In recent years, many preclinical studies on CAR-engineered NK (CAR-NK) cells have shown their remarkable efficacy in cancer therapy and their superiority over autologous CAR-T cells. In this review, we summarize the generation, mechanisms of anti-tumor activity and unique advantages of CAR-NK cells, and then analyze some challenges and recent clinical trials about CAR-NK cells therapy. We believe that CAR-NK therapy is a promising prospect for cancer immunotherapy in the future.

【 授权许可】

CC BY   
© The Author(s) 2022

【 图 表 】

Fig. 21

13046_2023_2672_Article_IEq1.gif